The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on December 10, 2025 for Aayush Agrawal, ....
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts more than Nifty Midcap 150 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aayush Agrawal, a promoter of Ajanta Pharma Ltd (acting as Trustee of Aayush Agrawal Trust), has filed a Regulation 31(1)/31(2) SAST disclosure with BSE and NSE on December 10, 2025, for creation of a pledge on 11,02,585 (about 11.02 lakh) equity shares of the company. The reason cited for creating the pledge is the upward movement in the share price, likely to avail additional borrowing against the appreciated value of shares. The note in the letter body that reads 'released pledge' appears to be an OCR artefact, as the subject line and standard SAST Form (Creation of Encumbrance) both consistently point to a pledge creation event.
Pledge creation by a promoter is a routine financing activity, but it does increase the encumbrance on promoter-held shares and is watched by investors. In this case, fresh pledge of ~11.02 lakh shares could marginally raise the total pledged promoter holding; it is not a sign of distress, but traders should monitor total pledged share percentage in the next shareholding pattern filing.